Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant
- Conditions
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 31
- Registration Number
- NCT04074174
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Montreal, Quebec, Canada
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 230
- Registration Number
- NCT04067999
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Álava, Spain
Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People
- Conditions
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 45
- Registration Number
- NCT04059367
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels
- Conditions
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 39
- Registration Number
- NCT04058834
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom
A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1122
- Registration Number
- NCT04042441
- Locations
- 🇸🇦
Saudi German Hospital, Jeddah, Saudi Arabia
🇸🇦My clinic, Jeddah, Saudi Arabia
🇮🇳Pace Diabetes Center, Bangalore, Karnataka, India
A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 101
- Registration Number
- NCT04032197
- Locations
- 🇦🇹
Clinical Trials Unit / Center for Medical Research, Graz, Austria
🇸🇪CTC Clinical Trial Consultants AB, Uppsala, Uppsala, Sweden
🇩🇰Steno Diabetes Center Copenhagen, Herlev, Denmark
A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
- Conditions
- Interventions
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT04016974
- Locations
- 🇨🇳
Beijing Hospital-phase I, Beijing, Beijing, China
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1441
- Registration Number
- NCT04017832
- Locations
- 🇩🇿
Maison des diabétiques El Harrach, Algiers, Algeria
🇩🇿Department of internal medicine hospital (CHU) of BIRTRARIA, Algiers, Algeria
🇧🇷Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda., Porto Alegre, Rio Grande Do Sul, Brazil
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 29
- Registration Number
- NCT04012255
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 103
- Registration Number
- NCT04010786
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States